Introduction
Fungal infections are a major cause of morbidity and mortality throughout the world (Ajello, 1971; Mycoses, 1975) and patients under induced immunosuppression for organ transplantation or receiving chemotherapy for cancer are susceptible to disease caused by 'opportunistic' organisms such as Aspergillus and Candida spp. (Bodey, 1977; Mason et al., 1976) . In spite of increasing awareness of the importance of fungal infections, there is a shortage of effective antimycotic agents and those that are available have drawbacks that limit their usefulness.
Amphotericin B has been the drug of choice for treatment of systemic fungal disease, but it is nephrotoxic and has other undesirable side effects (Bennett, 1974) . Flucytosine is less toxic than amphotericin but emergent fungal resistance to this drug is a potentially serious problem (Utz, 1977) . Newer antifungal agents such as miconazole and clotrimazole are still being evaluated.
The essence of effective chemotherapy is to exploit differences between host and pathogen so that the host is unaffected by the treatment. In fungal infections, exploitable differences are few because both host and pathogen are eukaryotes. However, an obvious difference between fungal and mammalian cells that has not been exploited is the presence in fungi of a polysaccharide cell wall that frequently contains chitin (Bartnicki-Garcia, 1968 A. fumigatus and Candida albicans were grown on glucose peptone medium containing (per litre) glucose 10 g, peptone 2 g, KH2PO4 0.5 g, MgSO4 0.5 g. Universal bottles containing 10 ml of this medium were inoculated with a spore suspension of A. fumigatus and incubated for 20 hr at 240C on a Luckham Rolamix blender. P. polycephalum was grown on the medium described by Carlile (1971 Results in Table 2 show that infected, untreated mice had a mean survival time of 13-5 days ( Davies, unpublished data) .
Acute toxicity tests with mycolases given intravenously or intraperitoneally in mice gave an LD50 of 15-20 mg/mouse (600-700 mg/kg).
Discussion
The fungal cell wall has been recognized by other workers as a potential target for therapeutic attack. Specific inhibitors of chitin synthetase, the polyoxins, have been developed (Endo, Kakiki and Misato, 1970) , but although these compounds are effective in vitro, they have not proved useful clinically. Chitinases occur widely in nature (Stirling, Cook and Pope, 1979) and, although their effects on fungal cell walls in vitro, alone and in conjunction with other enzymes are well known, as far as the authors are aware there have been no in vivo studies. Miura (1954) suggested that chitinase might be used for treating dermatophyte infections, but did not demonstrate mycocidal activity. The results show that chitinase alone is only slightly mycolytic and requires the presence of other enzymes before its full potential can be realized. The increased mycolytic activity of mycolases compared with the commercial enzyme mixture is almost certainly attributable to the wider range of carbohydrases they contain. Enzyme profiles for mycolases will be published elsewhere. ,, , Mycolases have been shown to be effective in both immune competent and immunosuppressed animals alone and in combination with existing antimycotic drugs (Davies and Pope, 1978) . The latter approach allows reduction in drug dosage and associated toxicity. In vitro tests suggest that addition of mycolase gives a 5-to 10-fold reduction in the MIC of a range of antifungal drugs. This is probably due to the increased access to the cell interior through the enzyme-damaged walls.
Mycolases have a wide spectrum of antifungal activity, are of low toxicity and there would seem to be only a remote chance of fungi developing resistance to their attack. The authors believe that mycolases hold considerable promise as an alternative to existing therapy for both systemic and superficial fungal infections.
